Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Pharmacosmos Drug Patent Portfolio

Pharmacosmos owns 2 orange book drugs protected by 19 US patents Given below is the list of Pharmacosmos's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12168666 Morphic forms of trilaciclib and methods of manufacture thereof 13 Nov, 2040
Active
US11529352 Preservation of immune response during chemotherapy regimens 23 Jul, 2039
Active
US12527798 05 Dec, 2037
Active
US11633489 Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant 22 Jun, 2036
Active
US8598186 CDK inhibitors 30 Dec, 2034
Active
US10085992 Transient protection of normal cells during chemotherapy 14 Mar, 2034
Active
US10966984 Transient protection of normal cells during chemotherapy 14 Mar, 2034
Active
US11717523 Transient protection of normal cells during chemotherapy 14 Mar, 2034
Active
US9487530 Transient protection of normal cells during chemotherapy 14 Mar, 2034
Active
US10189849 CDK inhibitors 25 Oct, 2031
Active
US10189850 CDK inhibitors 25 Oct, 2031
Active
US10927120 CDK inhibitors 25 Oct, 2031
Active
US11040042 Transient protection of normal cells during chemotherapy 25 Oct, 2031
Active
US8598197 CDK inhibitors 25 Oct, 2031
Active
US9957276 CDK inhibitors 25 Oct, 2031
Active
US8815301 Stable iron oligosaccharide compound 14 Aug, 2029
Active
US10414831 Stable iron oligosaccharide compound 25 Mar, 2029
Active
US11851504 Stable iron oligosaccharide compound 25 Mar, 2029
Active
US12030962 Stable iron oligosaccharide compound 25 Mar, 2029
Active


Given below is the list of recent legal activities going on the following drug patents of Pharmacosmos.

Activity Date Patent Number
Patent litigations
Information Disclosure Statement considered 15 Sep, 2025 US12527798
Disposal for a RCE / CPA / R129 12 Sep, 2025 US12527798
Date Forwarded to Examiner 12 Sep, 2025 US12527798
Request for Continued Examination (RCE) 11 Sep, 2025 US12527798
Information Disclosure Statement (IDS) Filed 11 Sep, 2025 US12527798
Workflow - Request for RCE - Begin 11 Sep, 2025 US12527798
PARALEGAL OR ELECTRONIC TERMINAL DISCLAIMER APPROVED 11 Sep, 2025 US12527798
Terminal Disclaimer Filed 11 Sep, 2025 US12527798
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 26 Jun, 2025 US11717523
Mail Notice of Allowance 18 Jun, 2025 US12527798
Notice of Allowance Data Verification Completed 17 Jun, 2025 US12527798
Information Disclosure Statement considered 10 Jun, 2025 US12527798
Date Forwarded to Examiner 08 Jun, 2025 US12527798
Disposal for a RCE / CPA / R129 08 Jun, 2025 US12527798
Workflow - Request for RCE - Begin 05 Jun, 2025 US12527798


Pharmacosmos's Family Patents

Pharmacosmos drugs have patent protection in a total of 30 countries. It's US patent count contributes only to 28.9% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Pharmacosmos Drug List

Given below is the complete list of Pharmacosmos's drugs and the patents protecting them.


1. Cosela

Cosela is protected by 14 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US12168666 Morphic forms of trilaciclib and methods of manufacture thereof 13 Nov, 2040
(14 years from now)
Active
US11529352 Preservation of immune response during chemotherapy regimens 23 Jul, 2039
(13 years from now)
Active
US12527798 05 Dec, 2037
(11 years from now)
Active
US8598186 CDK inhibitors 30 Dec, 2034
(8 years from now)
Active
US10085992 Transient protection of normal cells during chemotherapy 14 Mar, 2034
(7 years from now)
Active
US10966984 Transient protection of normal cells during chemotherapy 14 Mar, 2034
(7 years from now)
Active
US11717523 Transient protection of normal cells during chemotherapy 14 Mar, 2034
(7 years from now)
Active
US9487530 Transient protection of normal cells during chemotherapy 14 Mar, 2034
(7 years from now)
Active
US10189849 CDK inhibitors 25 Oct, 2031
(5 years from now)
Active
US10189850 CDK inhibitors 25 Oct, 2031
(5 years from now)
Active
US10927120 CDK inhibitors 25 Oct, 2031
(5 years from now)
Active
US11040042 Transient protection of normal cells during chemotherapy 25 Oct, 2031
(5 years from now)
Active
US8598197 CDK inhibitors 25 Oct, 2031
(5 years from now)
Active
US9957276 CDK inhibitors 25 Oct, 2031
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cosela's drug page


2. Monoferric

Monoferric is protected by 5 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11633489 Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant 22 Jun, 2036
(10 years from now)
Active
US8815301 Stable iron oligosaccharide compound 14 Aug, 2029
(3 years from now)
Active
US10414831 Stable iron oligosaccharide compound 25 Mar, 2029
(3 years from now)
Active
US11851504 Stable iron oligosaccharide compound 25 Mar, 2029
(3 years from now)
Active
US12030962 Stable iron oligosaccharide compound 25 Mar, 2029
(3 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Monoferric's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List